A Single-Blind, Placebo Run-in, Phase I/II Study Comparing Five Oral Doses of Proellex

Trial Profile

A Single-Blind, Placebo Run-in, Phase I/II Study Comparing Five Oral Doses of Proellex

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2014

At a glance

  • Drugs Telapristone (Primary)
  • Indications Dysmenorrhoea; Endometriosis; Menorrhagia; Uterine leiomyoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 15 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jan 2012 Status changed from recruiting to active, no longer recruiting.
    • 23 Jun 2011 Enrolment of patients in the fourth (9mg) cohort is underway, following a safety review of data from women who had completed 8 weeks of treatment at the 6mg dose, according to a Repros Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top